For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

Video

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.

While there are risks involved with CAR T-cell therapy, it could become a more popular therapy choice for younger patients with chronic lymphocytic leukemia (CLL) compared to bone marrow transplant, which can be even more difficult to tolerate, says Dr. Matthew Davids of the Dana-Farber Cancer Institute.

In an interview with CURE®, Davids explained that younger patients with CLL, particularly those with more high-risk disease who have relapsed despite a number of previous treatments, could find CAR T-cell therapy treatment a more tolerable option than the standard of allogeneic transplantation.

By harnessing and reprogramming the body’s own cells to fight cancer, CAR T-cell therapy has had success in a number of other cancer types in the past decade or so, Davids noted. And while it’s not currently approved for use in CLL, it is being examined in various combinations that could prove successful down the road.

Transcription:

One other thing that comes to mind as we think about where the field is headed in the future is that we've seen some early but promising data for CAR T-cell based therapies. This is using the patient's own T lymphocyte cells, educating them outside the body and then reinfusing them to try to have a sustained response to CLL.

And although this is not yet an FDA approved treatment in CLL, I think it's showing promise. I think about it for my younger patients, particularly those who have maybe been through a few lines of CLL treatment already, particularly if they have very high-risk disease like the TP53 deletion or mutation. You know, currently, those are patients we think about bone marrow transplant, allogeneic transplantation for, but that certainly has some very serious risks. And even though CAR T-cell therapy also has risks, I think, in general, the toxicity profile is more favorable than allogeneic transplantation.

We've started to see some patients with very long-term remissions now from CAR T. So I'm excited to see the how that field evolves in the coming years. There are people exploring various combinations of different drugs with CAR T. And so, I think the technology and the combination therapies will improve over time. And so I do think that for younger patients who have a long time horizon, that could eventually be an approved option to think about down the road.

Related Videos
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Yuliya P.L Linhares, MD, an expert on CLL
Video 8 - "Acalabrutinib-Based Treatment Clinical Trial Updates"
Video 7 - "Overview of Efficacy and Safety Data for Current CLL Treatment Options"
Josie Montegaard, MSN, AGPCNP-BC, an expert on CLL
Yuliya P.L Linhares, MD, an expert on CLL
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL